Literature DB >> 14529923

Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.

J Ziolkowski1, L Paczek, G Senatorski, M Niewczas, U Oldakowska-Jedynak, J Wyzgal, J Sanko-Resmer, T Pilecki, K Zieniewicz, P Nyckowski, W Patkowski, M Krawczyk.   

Abstract

Renal failure, mainly due to calcineurin inhibitor (CNI) nephrotoxicity, is the most common complication following orthotopic liver transplantation (ltx). The aim of this study was to evaluate the incidence and course of renal failure in adult ltx patients. Severe acute renal failure in early postoperative period due to impaired hemodynamics and CNI nephrotoxicity, occurred in 14 patients, 3 of whom required dialysis. The creatinine clearance after ltx showed a tendency to decrease, but there was no statistically significant difference (P >.05) in the change in serum creatinine clearance levels between patients treated with tacrolimus (TAC) versus Cyclosporine (CsA) during the first 2 years of follow-up. Fourteen patients required conversion of their regimen because of CNI nephrotoxicity namely, dose reduction (n = 7) or discontinuation of CNI therapy with the replacement by mycophenolate mofetil (MMF) (n = 5) or SRL (n = 5). Dose reduction or CNI withdrawal significantly improved the creatinine clearance (P <.05) without affecting lives graft function. No episode of acute rejection was observed after conversion. Neither conversion of CsA to TAC nor the reverse maneuver significantly influenced the serum creatinine level (P >.05). Reduction of the CNI dose or CNI discontinuation or replacement with MMF or SRL in patients with stable liver but impaired renal function is safe, resulting in a significant improvement in renal function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529923     DOI: 10.1016/s0041-1345(03)00786-3

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.

Authors:  Martin-Walter Welker; Nina Weiler; Wolf Otto Bechstein; Eva Herrmann; Christoph Betz; Mark Schöffauer; Stefan Zeuzem; Christoph Sarrazin; Kerstin Amann; Oliver Jung
Journal:  J Nephrol       Date:  2018-06-26       Impact factor: 3.902

Review 2.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil.

Authors:  Masami Minemura; Yoshiharu Tokimitsu; Kazuto Tajiri; Yasuhiro Nakayama; Kengo Kawai; Hiroshi Kudo; Katsuharu Hirano; Yoshinari Atarashi; Yutaka Yata; Satoshi Yasumura; Terumi Takahara; Toshiro Sugiyama
Journal:  World J Hepatol       Date:  2010-12-27

4.  Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?

Authors:  Monika Wieliczko; Urszula Ołdakowska-Jedynak; Jolanta Małyszko
Journal:  Ann Transplant       Date:  2020-10-20       Impact factor: 1.530

5.  Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction.

Authors:  Jose Iglesias; Elliot Frank; Sushil Mehandru; John M Davis; Jerrold S Levine
Journal:  BMC Nephrol       Date:  2013-07-13       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.